What is KeyBanc's new rating for Salesforce?

KeyBanc lowered its rating from Overweight to Sector Weight, with no new price target specified.

Did PepsiCo earnings impact the market?

PepsiCo made headlines after reporting quarterly earnings, but the article did not provide specific details on market impact.

What happened with AstraZeneca's trial?

AstraZeneca announced a failed clinical trial for a new drug, negatively impacting its stock.

Salesforce Stock Dips on KeyBanc Downgrade; AstraZeneca Trial Miss

Salesforce (CRM) shares declined on Thursday after KeyBanc downgraded the stock from Overweight to Sector Weight. Meanwhile, AstraZeneca (AZN) announced a clinical trial miss, and PepsiCo (PEP) reported quarterly earnings.

July 9, 2026

2 min read

Source: Yahoo Finance Video

Salesforce (CRM) shares dipped on Thursday following a downgrade by KeyBanc from Overweight to Sector Weight. Separately, AstraZeneca (AZN) disclosed a failed clinical trial for a new drug, weighing on its stock. PepsiCo (PEP) also made headlines after releasing its quarterly results.

Rating Change

KeyBanc lowered its rating on Salesforce from Overweight to Sector Weight. No new price target was provided in the report.

Analyst Rationale

The analyst cited concerns over slowing revenue growth and intensifying competition in the CRM market. Additionally, cautious corporate spending on software was flagged as a headwind for Salesforce.

Context

The downgrade comes amid a relatively weak performance for Salesforce this year, as it faces pressure from rivals like Microsoft (MSFT). However, the majority of analysts still rate the stock as a Buy.

What to Make of It

KeyBanc's downgrade reflects a cautious stance on Salesforce given sector headwinds, but it does not represent a consensus. Investors should monitor the company's upcoming earnings and guidance for clearer signals on growth trajectory.

Frequently Asked Questions

Salesforce shares fell after KeyBanc downgraded the stock from Overweight to Sector Weight, citing concerns over slowing growth and rising competition.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.